medigraphic.com
SPANISH

Enfermedades Infecciosas y Microbiología

  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

1999, Number 2

<< Back Next >>

Enf Infec Microbiol 1999; 19 (2)

Pulmonary mucormycosis. A case report with satisfactory response to amphotericin B treatment, without surgery

Velázquez LA, Quant DC, Ruiz PG
Full text How to cite this article

Language: Spanish
References: 11
Page: 77-79
PDF size: 111.44 Kb.


Key words:

pulmonary mucormycosis, amphotericin B, Mucor spp.

ABSTRACT

Mucormycosis is an opportunistic infection caused by fungi belonging to zigomycete-class. This article presents a 40-year-old male whose entity started with acute diarrhea with hypovolemic shock 15 days before he was entered to Instituto Nacional de la Nutrición Salvador Zubirán, where we found him hypotensive, tachycardic, confused and postrated as well as with polypnea, diaphoresis and mild deshydratation. Thorax radiography showed an extensive consolidation area at left parahiliar region. Patient was hospitalized at intensive therapy unit where a broncoscopy and transbronchial biopsy were made. Mucor spp was isolated in cultures. We started treatment with amphotericin B 1 mg/kg/d. Patient satisfactorily evolved, and was discharged having an amphotericin B accumulated dose of 1.5 g. At this moment he does not have clinical sequelae and a control thorax axial tomography revealed a complete resolution of pneumonic process, even though a pulmonary fibrosis image at left lung apical region persists. Mucormycosis is acquired by inhaling the microorganism. A previous bacterial infection may make easier the superinfection by Mucor. The successful treatment of pulmonary mucormycosis is generally achieved with an early diagnosis and antifungal therapy and with the control of the underlying disease, amphotericin B continues to be the most reliable agent to treat mucormycosis.


REFERENCES

  1. Fan KT, Whitman GJ, Chew FS. Pulmonary zygomicosis. Roentgenology 1996;167:946.

  2. Bigby TD, Serota ML, et al. Clinical spectrum of pulmonary murcomycosis. Chest 1986;89:435-9.

  3. Husari AW, Jensen WA, et al. Pulmonary mucormycosis presenting as an endobronchial lesion. Chest 1994;106:1889- 91.

  4. Nollaig A, Parfrey. Improved diagnosis an prognosis of mucormycosis. Medicine 1986;65:113-23.

  5. Record NB, Ginder DR. Pulmonary phycomycosis without obvious predisponsing fators. JAMA 1976;235:1256-7.

  6. Lehrer RI, Howard DH, Sypherd PS, et al. Mucormycosis. Ann Inter Med 1980;93:93-108.

  7. Fukushima T, Zumazaki R, et al. Successful treatment of invasive thoracopulmonary mucormycosis in a patient with acute lymphoblastic leukemia. Cancer 1995;76:895-9.

  8. Donohue JF. Endobronchial mucormycosis. Chest 19983;83: 585.

  9. Berns JS, Lederman MM, Greene DM. Nonsurgical cure of pulmonary mucormycosis. Am J Med Sci 1984;287:42-4.

  10. Medoff G, Kobayashi GS. Pulmonary mucormycosis. N Engl J Med 1981;282:86-7.

  11. Berns JS, Lederman MM, Greene BM. Nonsurgical cure of pulmonary mucormycosis. 1984; 287:42-4.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Enf Infec Microbiol. 1999;19